MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT) will hold its Annual Shareholders Meeting virtually on June 12, 2024, starting at 9:30 a.m. ET. Shareholders can register from 9:15 a.m. ET by visiting www.virtualshareholdermeeting.com/INKT2024 and using their 16-digit control number from proxy materials. Guests can access the meeting in listen-only mode without a control number. A live webcast and replay will be available on the company's website.
Positive
- The virtual format increases accessibility for all shareholders to participate.
- The company provides a live webcast and replay option, ensuring shareholders can access the meeting content conveniently.
- Clear instructions for registration and participation are provided, enhancing shareholder engagement.
Negative
- The announcement did not include any new financial data or updates on clinical trials, which might disappoint investors looking for substantive news.
- A virtual-only format may pose challenges for less tech-savvy shareholders.
News Market Reaction – INKT
In the trading session that priced this news, INKT gained 0.49%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 12, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.
To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests.
Webcast Information:
Date: Wednesday, June 12, 2024
Time: 9:30 a.m. ET
A live webcast and replay will be accessible from the Company's website at https://investor.minktherapeutics.com/events-and-presentations and at www.virtualshareholdermeeting.com/INKT2024.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Investor Contact
917-362-1370
Media Contact
781-674-4428
communications@minktherapeutics.com
